National Taiwan University

CerbACT Asia Holds Ribbon Cutting to Celebrate New Immuno-oncology Centre of Excellence

Thursday, October 7, 2021 - 10:48am

The opening ceremony held on the 30th September 2021, was attended by distinguished guests virtually and in-person, marking the start of operations and expansion of the precision medicine offer in Asia.

Key Points: 
  • The opening ceremony held on the 30th September 2021, was attended by distinguished guests virtually and in-person, marking the start of operations and expansion of the precision medicine offer in Asia.
  • "Everyone here at CerbACT Asia is fully committed to provide high-quality results to our clients and hope to improve patient outcomes through precision medicine," says Dr George Wei, Managing Director of CerbACT Asia.
  • Together, we offer a broader range of top-notch technologies and services in Asia.
  • CerbACT Asia is an Immuno-Oncology Centre of Excellence that empowers precision medicine development and drives better patient outcomes by applying deep biomarker expertise to research and clinical development strategies.

IMPACT Therapeutics Appoints Dr. Chun-Pyn Shen as Head of Regulatory Affairs

Thursday, September 30, 2021 - 5:00pm

SHANGHAI, Sept. 30, 2021 /PRNewswire/ -- IMPACT Therapeutics announced that Dr. Chun-Pyn Shen was appointed as Head of Regulatory Affairs (Vice President).

Key Points: 
  • SHANGHAI, Sept. 30, 2021 /PRNewswire/ -- IMPACT Therapeutics announced that Dr. Chun-Pyn Shen was appointed as Head of Regulatory Affairs (Vice President).
  • Reporting to CEO directly, Dr Shen will lead the Department of Regulatory Affairs which is responsible for the formulation and execution of global regulatory strategy for all IMPACT pipeline products.
  • "I am thrilled to join IMPACT Therapeutics as Head of Regulatory Affairs.
  • IMPACT Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality.

The First Performance Art NFT Exhibition Of EchoX, A Million-dollar Vision On Its Debut, Overturns The Game

Friday, September 17, 2021 - 12:12pm

Though the NFT market is hot, much of the focus has been on creating digital art by digital creators.

Key Points: 
  • Though the NFT market is hot, much of the focus has been on creating digital art by digital creators.
  • Empowering an art by minting an NFT as the corresponding traceable anti-counterfeiting certificates mapped to the original artwork.
  • EchoX, COO Kuan-Ting Liu said,"It is foreseeable that more art trading will take place online through virtual certificates, NFT, which also echoes the original vision of EchoX.
  • EchoX is the online-offline curating expert, providing NFT management tools and consulting services in online curating.

ABVC BioPharma Completes Site Selection for ABV-1505 ADHD Phase II Part 2 Clinical Study

Monday, September 13, 2021 - 1:30pm

FREMONT, CA, Sept. 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it has completed clinical site selection for its ABV-1505 Attention-Deficit Hyperactivity Disorder (ADHD) Phase II Part 2 study.  The Phase II, Part 1 study, completed at the University of California, San Francisco, was accepted by the US Food & Drug Administration in October 2020. The Part 2 study of ABV-1505 (ADHD) is a multi-nation multi-site randomized, double-blind, placebo-controlled study involving approximately 100 patients.

Key Points: 
  • FREMONT, CA, Sept. 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it has completed clinical site selection for its ABV-1505 Attention-Deficit Hyperactivity Disorder (ADHD) Phase II Part 2 study.
  • The Phase II, Part 1 study, completed at the University of California, San Francisco, was accepted by the US Food & Drug Administration in October 2020.
  • The Part 2 study of ABV-1505 (ADHD) is a multi-nation multi-site randomized, double-blind, placebo-controlled study involving approximately 100 patients.
  • ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development.

LXT to Capitalize on Massive Opportunity in AI Training Data with Agile and Customized Solutions, Expanded Management Team and Exclusive Partnership

Tuesday, August 31, 2021 - 2:00pm

- Mohammad Omar, CEO

Key Points: 
  • - Mohammad Omar, CEO
    Since 2014, LXT has provided agile, customized, high-performance and secure global data generation, collection and annotation services to AI innovators around the world.
  • Data annotation requires countless hours of human intelligence and translation while data hungry businesses need reliable data collection and annotation partners with global coverage.
  • Data annotation- LXT delivers meticulous, human-annotated data that generates fully comprehensible, tagged, and structured assemblages for enterprise-grade AI models.
  • LXT is an emerging leader in AI training data to power intelligent technology for global organizations, including the largest technology companies in the world.

NVIDIA Founder and CEO Jensen Huang to Receive Semiconductor Industry's Top Honor

Thursday, August 12, 2021 - 5:06pm

WASHINGTON, Aug. 12, 2021 /PRNewswire/ -- The Semiconductor Industry Association (SIA) today announced Jensen Huang, founder and CEO of NVIDIA (NASDAQ:NVDA) and a trailblazer in building accelerated computing platforms, is the 2021 recipient of the industry's highest honor, the Robert N. Noyce Award .

Key Points: 
  • WASHINGTON, Aug. 12, 2021 /PRNewswire/ -- The Semiconductor Industry Association (SIA) today announced Jensen Huang, founder and CEO of NVIDIA (NASDAQ:NVDA) and a trailblazer in building accelerated computing platforms, is the 2021 recipient of the industry's highest honor, the Robert N. Noyce Award .
  • We're pleased to recognize Jensen with the 2021 Robert N. Noyce Award for his many achievements in advancing semiconductor technology."
  • Huang founded NVIDIA in 1993 and has served since its inception as CEO and a member of the board of directors.
  • The Noyce Award is named in honor of semiconductor industry pioneer Robert N. Noyce, co-founder of Fairchild Semiconductor and Intel Corporation.